GnRH and LHRgene variants predict adverse outcome in premenopausal breast cancer patients

Breast Cancer Research

Table 1 Baseline characteristics in 278 premenopausal patients according to LHR insLQ and GnRH 16Ser carriership

		LHR insLQ			GnRH 16Ser
Feature	Number (percent)	Non-carriers (percent)	Carriers (percent)^a	P value^a	Non-carriers (percent)	Carriers (percent)	P value^a
Breast cancer cases	278 (100)	147 (53)	131 (47)		157 (56)	121 (44)
Age in years				0.18			0.56
<35	19 (7)	12	7		9	10
35–39	35 (12)	13	22		17	18
40–49	167 (60)	93	74		99	68
50–59	57 (21)	29	28		32	25
Node status				0.78			0.001 ^b
Negative	134 (48)	72	62		89	45
Positive	144 (52)	75	69		68	76
Histological grade ^c				0.04			0.15
Well/mod	66 (24)	44	22		41	25
unknown	59 (21)	28	31		27	32
Poor	153 (55)	75	78		89	64
Tumor size ^d				0.58			0.30
≤2 cm	113 (41)	62	51		68	45
>2 cm	165 (59)	85	80		89	76
Estrogen receptor status ^c,e				0.095			0.29
Negative	78 (28)	35	43		48	30
Positive	200 (72)	112	88		109	91
Progesterone receptor status ^c,e				0.15			0.54^f
Negative	70 (25)	32	38		42	28
Positive	199 (72)	111	88		111	88
HER2 amplified ^c				0.68			0.85
Yes	55 (20)	28	27		30	25
No	202 (73)	106	96		114	88
Adjuvant therapy				0.54			0.09
No	158 (57)	88	70		96	62
Hormonal	4 (1)	1	3		1	3
Chemotherapy	110 (40)	55	55		55	55
Combined	6 (2)	3	3		5	1

^aχ² test. ^bAlso, when stratified per 'genotype', P = 0.003. ^cNumbers in cells may not add up due to incomplete information on histological grade and/or receptor status. ^dTumors of unknown size (n = 10) are included as tumor size >2 cm. ^eThe cutoff value used was 10 fmol/mg protein. ^fSignificant when stratified per 'genotype', P = 0.02. Entries in bold represent significant outcomes.

ISSN: 1465-542X